Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations

Journal of Immunology

Volumn 171, Issue 8, 2003, Pages 4164-4174

  Liu, Kebin ^a   McDuffie, Elwood ^a   Abrams, Scott I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIBODY; FAS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOMA CELL; CELL SUBPOPULATION; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NATURAL SELECTION; NONHUMAN; OUTCOMES RESEARCH; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

EID: 0141958153     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.8.4164     Document Type: Article

References (51)

1. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100:57.
2. Kaufmann, S. H., and W. C. Earnshaw. 2000. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256:42.
3. Henkart, P. A. 1996. ICE family proteases: mediators of all apoptotic cell death? Immunity 4:195.
4. Nagata, S. 1997. Apoptosis by death factor. Cell 88:355.
5. Russell. J. H., and T. J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20:323.
6. Saha, S., A. Bardelli, P. Buckhaults, V. E. Velculescu, C. Rago, B. St. Croix, K. E. Romans, M. A. Choti, C. Lengauer, K. W. Kinzler, and B. Vogelstein. 2001. A phosphatase associated with metastasis of colorectal cancer. Science 294:1343.
7. Wang, T. L., C. Rago, N. Silliman, J. Ptak, S. Markowitz, J. K. Willson, G. Parmigiani, K. W. Kinzler, B. Vogelstein, and V. E. Velculescu. 2002. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc. Natl. Acad. Sci. USA 99:3076.
8. Fidler, I. J. 2002. Critical determinants of metastasis. Semin. Cancer Biol. 12:89.
9. Van Parijs, L., and A. K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243.
10. Moller, P., K. Koretz, F. Leithauser, S. Bruderlein, C. Henne, A. Quentmeier, and P. H. Krammer. 1994. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57:371.
11. Krammer, P. H. 1999. CD95 (APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71:163.
12. Leibovitz, A., J. C. Stinson, W. B. McCombs III, C. E. McCoy, K. C. Mazur, and N. D. Mabry. 1976. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36:4562.
13. Hewitt, R. E., A. McMarlin, D. Kleiner, R. Wersto, P. Martin, M. Tsokos, G. W. Stamp, W. G. Stetler-Stevenson, and M. Tsoskas. 2000. Validation of a model of colon cancer progression. J. Pathol. 192:446.
14. + CTL. J. Immunol. 164:4941.
15. Itoh, N., S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Sameshima, A. Hase, Y. Seto, and S. Nagata. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233
16. Gorczyca, W., S. Bruno, R. J. Darzynkiewicz, J. Gong, and Z. Darzynkiewicz. 1992. DNA strand breaks occurring in apoptosis: their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int. J. Oncol. 1:639.
17. Gorczyca, W., K. Bigman, A. Mittelman, T. Ahmed, J. Gong, M. R. Melamed, and Z. Darzynkiewicz. 1993. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 7:659.
18. Hara, I., H. Miyake, S. Hara, S. Arakawa, and S. Kamidono. 2000. Differential involvement of the Fas receptor/ligand system in p53-dependent apoptosis in human prostate cancer cells. Prostate 45:341.
19. Thorne, M., P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattmann, K. Burns, J. L. Bodmer, M. Schroter, et al. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors, Nature 386:517.
20. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863.
21. + cytotoxic T lymphocyte attack. Cancer Immunol. Immunother. 49:193.
22. Siegel, R. M., F. K. Chan, H. J. Chun, and M. J. Lenardo. 2000. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immun. 1:469.
23. Bos, J. L. 1988. The ras gene family and human carcinogenesis. Mutat. Res. 195:255.
24. Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11.
25. Hall, A. 1998. Rho GTPases and the actin cytoskeleton. Science 279:509.
26. Clark, E. A., T. R. Golub, E. S. Lander, and R. O. Hynes. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532.
27. Ramaswamy, S., K. N. Ross, E. S. Lander, and T. R. Golub. 2003. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:49.
28. Zhang, L., Y. K. Lau, L. Xi, R. L. Hong, D. S. Kim, C. F. Chen, G. N. Hortobagyi, C. Chang, and M. C. Hung. 1998. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16:2855.
29. Toyama, T., H Iwase, H. Yamashita, Y. Hara, Y. Omoto, H. Sugiura, Z. Zhang, and Y. Fujii. 2003. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett. 189:97.
30. Kim, Y. W., H. Wang, I. Sures, R. Lammers, K. J. Martell, and A. Ullrich. 1996. Characterization of the PEST family protein tyrosine phosphatase BDPI. Oncogene 13:2275.
31. Lang, S. H., C. Hyde, I. N. Reid, I. S. Hitchcock, C. A. Hart, A. A. Bryden, J. M. Villette, M. J. Stower, and N. J. Maitland. 2002. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52:253.
32. Cohen, G. M. 1997. Caspases: the executioners of apoptosis. Biochem. J. 326:1.
33. Zuzak, T. J., D. F. Steinhoff, L. N. Sutton, P. C. Phillips, A. Eggert, and M. A. Grotzer. 2002. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur. J. Cancer 38:83.
34. Yang, X., M. S. Merchant, M. E. Romero, M. Tsokos, L. H. Wexler, U. Kontny, C. L. Mackall, and C. J. Thiele. 2003. Induction of caspase 8 by interferon γ renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 63:1122.
35. Hara, I., S. Hara, H. Miyake, S. Arakawa, and S. Kamidono. 2001. Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines. Int. J. Oncol. 18:1181.
36. +-binding modulator protein involved in cell proliferation and in cell death. Biochim. Biophys. Acta 1600:68.
37. Gilboa, E. 1999. How tumors escape immune destruction and what we can do about it. Cancer Immunol. Immunother. 48:382.
38. Pawelec, G. 1999. Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol. Immunother. 48:343.
39. Ferrone, S., J. F. Finerty, E. M. Jaffee, and G. J. Nabel. 2000. How much longer will tumour cells fool the immune system? Immunol. Today 21:70.
40. Levitsky, H. I. 2000. Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance. Cancer J. Sci. Am. 6(Suppl. 3):S281.
41. Restifo, N. P. 2000. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 6:493.
42. Igney, F. H., and P. H. Krammer. 2002. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukocyte Biol. 71:907.
43. Owen-Schaub, L. B., K. L. van Golen, L. L. Hill, and J. E. Price. 1998. Fas and Fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. 188:1717.
44. Djerbi, M., V. Screpanti, A. I. Catrina, B. Bogen, P. Biberfeld, and A. Grandien. 1999. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190:1025.
45. Medema, J. P., J. de Jong, T. van Hall, C. J. Melief, and R. Offringa. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190:1033.
46. Maecker, H. L., Z. Yun, H. T. Maecker, and A. J. Giaccia. 2002. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2:139.
47. Krammer, P. H., P. R. Galle, P. Moller, and K. M. Debatin. 1998. CD95 (APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv. Cancer Res. 75:251.
48. Owen-Schaub, L. B., R. Radinsky, E. Kruzel, K. Berry, and S. Yonehara. 1994. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1580.
49. Owen-Schaub, L. B., H. Chan, J. C. Cusack, J. Roth, and L. L. Hill. 2000. Fas and Fas ligand interactions in malignant disease. Int. J. Oncol. 17:5.
50. Liu, K., and S. I. Abrams. 2003. Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-γ. J. Immunol. 170:6329.
51. Liu, K., and S. I. Abrams. 2003. Alterations in Fas expression are characteristic of, but not solely responsible for enhanced metastatic competence. J. Immunol. 170:5973.